What are the benefits and harms of using a dihydropyridine calcium channel blocker or an ARB as the first-line antihypertensive agent in adult kidney transplant recipients?
Using a dihydropyridine calcium channel blocker or an ARB as the first-line antihypertensive agent in adult kidney transplant recipients can help to prevent kidney allograft loss. However, there is a risk of possible medication-related side effects. In the judgment of the Work Group, the potential prevention of transplant failure outweighs potential risks of burden associated with its implementation, and all or nearly all well-informed transplant patients would choose to receive a CCB or an ARB given the potential benefit. 